Skip to content
AnalystLens

IDEXX Laboratories 8-K Report, Financial Results (Aug 4, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed August 4, 2025
Period End
August 4, 2025
Security
IDXX
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’19Oct ’19
  2. Material agreement8-K · Dec ’21Dec ’21
  3. Leadership change8-K · May ’24May ’24

Summary

Summary of the 8-K filed August 4, 2025. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories reported second quarter 2025 revenue of $1,109 milliona, up 11% as reported and 9% organic, with Companion Animal Group (CAG) growing 11% reported and 10% organic.

CAG Diagnostics recurring revenue grew 9% reported and 7% organic, led by 15% reported growth in IDEXX VetLab consumables and record quarterly instrument placements, including nearly 2,400 IDEXX inVue Dx analyzers. Diluted EPS was $3.63b, up 49% as reported but only 17% on a comparable basis, which strips out a $0.56 benefit from lapping the prior-year $61.5 million litigation accrual and a $0.07 discrete tax reserve release. Gross margin expanded 90 basis points to 62.6%, and operating margin rose to 33.6% (up 130 basis points on a comparable basis).

Management raised its 2025 guidance. Revenue is now expected at $4,205 million to $4,280 millionc (7.7% to 9.7% reported growth, 7% to 9% organic), an increase of about $90 million at the midpoint, of which roughly $70 million reflects favorable foreign exchange. The EPS outlook rose to $12.40 to $12.76, a $0.40 increase at the midpoint that includes $0.22 from FX and $0.09 from higher share-based compensation benefits.

Comparable operating margin expansion of 50 to 80 basis points was maintained, and the company is planning commercial expansion in select international regions in the second half. Balance sheet and cash flow warrant attention. Free cash flow for the first half was $359.6 milliond, versus $383.3 million a year earlier.

Cash fell to $164.6 million, the line of credit rose to $579 million from $250 million at year-end 2024, and the company repurchased roughly $739 million of stock in the first six months. Investors should also note that the company will hold its 2025 Investor Day on August 14, 2025.

Key Highlights

  1. Revenue of $1,109 million grew 11% as reported and 9% organic; CAG grew 11% reported and 10% organic.
  2. Diluted EPS of $3.63 rose 49% as reported but 17% on a comparable basis, excluding a $0.56 prior-year litigation comparison benefit and a $0.07 discrete tax reserve release.
  3. Record quarterly CAG Diagnostics instrument placements, including nearly 2,400 IDEXX inVue Dx analyzers; CAG Diagnostics capital instrument revenue rose 66% reported.
  4. IDEXX VetLab consumables grew 15% reported and 14% organic, with a 10% increase in the global premium instrument installed base.
  5. 2025 revenue guidance raised to $4,205M-$4,280M (about +$90M at midpoint, of which ~$70M is FX); EPS guidance raised to $12.40-$12.76 (+$0.40 at midpoint).
  6. Gross margin expanded 90 bps to 62.6%, and operating margin rose 730 bps to 33.6% (130 bps comparable) after lapping the prior-year $61.5M litigation charge.
  7. Cash fell to $164.6M while the credit line balance rose to $579M and first-half share repurchases reached about $739M, leaving free cash flow of $359.6M for the first half versus $383.3M a year earlier.

Frequently Asked Questions

  1. What drove the large reported increase in EPS?

    Diluted EPS rose 49% to $3.63, but most of that reflects the lapping of a $61.5 million litigation accrual recorded in Q2 2024, which contributed $0.56 to the comparison. Comparable EPS growth was 17%, and the quarter also included a $0.07 discrete tax reserve release and $0.10 of share-based compensation tax benefits.

  2. Is the 2025 guidance increase driven by the core business or by currency?

    Both. The revenue raise of about $90 million at the midpoint is roughly 2 percentage points and includes about $70 million from foreign exchange, with the remainder from solid CAG Diagnostics recurring revenue and higher expected inVue Dx placements. The EPS raise of $0.40 includes $0.22 from FX, $0.11 from operations, $0.09 from share-based compensation, and a net $0.02 tax effect. Organic growth guidance was raised by 50 basis points at the midpoint.

  3. What should investors watch on the balance sheet?

    Borrowings on the credit line increased to $579 million from $250 million at year-end 2024, and cash declined to about $165 million, as the company returned capital through roughly $739 million of buybacks in the first half. First-half operating cash flow was $423.7 million, down from $446.9 million, and free cash flow conversion guidance of 80% to 85% of net income is unchanged.

  4. What is the outlook for margins and expenses in the second half?

    Management maintained comparable operating margin expansion of 50 to 80 basis points for 2025 and reported full-year operating margin of 31.3% to 31.6%. It expects to add commercial spending in select international regions in the second half and a modest U.S. expansion to support its growing diagnostic portfolio, which may limit margin upside.